

**Chair**

Ryan D. Niederkoehr, MD  
Santa Clara, California

**Vice Chair**

Liza Lindenberg, MD  
Bethesda, Maryland

**Secretary Treasurer**

Maria Rosana Ponisio, MD  
Saint Louis, Missouri

**Past Chair**

Gholam Reza Berenji, MD, MS  
Los Angeles, California

**Directors**

Twyla Bartel, DO, MBA  
Tulsa, Oklahoma

Lisa Bodei, MD, PhD  
New York, New York

Benjamin L. Franc, MD, MS, MBA  
Stanford, California

K. Elizabeth Hawk, MS, MD, PhD  
Studio City, California

Hossein Jadvar, MD, PhD, MPH, MBA  
Los Angeles, California

Hollie Anne Lai, MD  
Orange, CA

Yusuf Menda, MD  
Iowa City, Iowa

Medhat M. Osman, MD, ScM, PhD  
Saint Louis, Missouri

**Executive Director**

George M. Segall, MD  
Palo Alto, California

**Associate Executive Director**

Kirk A. Frey, MD, PhD  
Ann Arbor, Michigan

**Administrator**

Maria J. Watts, MBA  
Saint Louis, Missouri

March 21, 2023

Dear Nuclear Medicine Program Director:

In November 2020 the ABNM sent a letter (via email) to Nuclear Medicine Program Directors regarding the [ABNM provisional criteria requirements for radionuclide therapy](#).

As stated in our previous correspondence, we periodically re-evaluate radionuclide therapy requirements for initial certification. The ABNM has decided to extend the provisional requirements. **We will continue accepting the ACGME Nuclear Medicine program requirements or ABNM provisional, requirements for the 2023 and 2024 ABNM Initial Certification Examination** as outlined below:

ABNM Requirements Radionuclide Therapy		
	AGGME Current Criteria <i>(in effective since 2014)</i>	ABNM Provisional Criteria <i>(accepted in 2021 and 2022)</i>
I-131 ≤ 33 mCi (benign)	10 – 15	5+
I-131 > 33 mCi (malignant)	10 – 15	5+
Parenteral	5	*10+
<b>Total Therapies</b>	<b>35</b>	<b>35</b>
<b>*At least 2 different FDA approved radiopharmaceuticals excluding <sup>90</sup>Y microspheres</b>		

The ABNM will require all candidates using the ABNM provisional pathway to submit [a training record](#) that includes the date of treatment, radiopharmaceutical, and administered dose.


The ABNM believes that the new criteria will improve resident training, give Nuclear Medicine Program Directors more flexibility in meeting ABNM requirements, and maintain high standards for the specialty. We will re-evaluate requirements for radionuclide therapy based on this information and the state of practice in 2024.

As always, thank you for supporting Nuclear Medicine training at your institution, and training young professionals to be the future leaders of our specialty.

You may send your questions or comments to [abnm@abnm.org](mailto:abnm@abnm.org).

Sincerely,

  
Ryan D. Niederkoehr, MD  
Chair

  
George Segall, MD  
Executive Director

RDN/GMS/mrf